## Veli-Pekka Harjola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/167873/publications.pdf

Version: 2024-02-01

100 papers

7,695 citations

39 h-index 85 g-index

104 all docs

104 docs citations

times ranked

104

7606 citing authors

#	Article	IF	CITATIONS
1	The use of diuretics in heart failure with congestion â€" a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	7.1	605
2	Epidemiology and oneâ€year outcomes in patients with chronic heart failure and preserved, midâ€range and reduced ejection fraction: an analysis of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1574-1585.	7.1	568
3	Clinical picture and risk prediction of shortâ€ŧerm mortality in cardiogenic shock. European Journal of Heart Failure, 2015, 17, 501-509.	7.1	520
4	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	7.1	455
5	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <scp>ESC</scp> Heart Failure Long‶erm Registry. European Journal of Heart Failure, 2017, 19, 1242-1254.	7.1	339
6	Recommendations on preâ€hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	7.1	315
7	Epinephrine Versus Norepinephrine forÂCardiogenic Shock After AcuteÂMyocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 173-182.	2.8	282
8	Risk Stratification for Patients inÂCardiogenic Shock After AcuteÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2017, 69, 1913-1920.	2.8	269
9	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2017, 19, 821-836.	7.1	252
10	Epidemiology, pathophysiology and contemporary management of cardiogenic shock–Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
11	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
12	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure, 2010, 12, 239-248.	7.1	214
13	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. Journal of the American College of Cardiology, 2014, 63, 778-785.	2.8	213
14	Acute heart failure congestion and perfusion statusÂâ€"Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	7.1	170
15	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 3-15.	7.1	157
16	Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Critical Care, 2016, 20, 208.	5.8	145
17	Management of cardiogenic shock complicating myocardial infarction. Intensive Care Medicine, 2018, 44, 760-773.	8.2	126
18	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123

#	Article	IF	CITATIONS
19	Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 2018, 39, 17-25.	2.2	111
20	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine, 2018, 44, 847-856.	8.2	106
21	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. European Heart Journal, 2020, 41, 509-518.	2.2	106
22	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Journal, 2015, 36, 1958-1966.	2.2	105
23	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International Journal of Cardiology, 2016, 222, 303-312.	1.7	103
24	Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest. JAMA - Journal of the American Medical Association, 2016, 315, 1120.	7.4	97
25	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensityâ€score matched study. European Journal of Heart Failure, 2018, 20, 345-354.	7.1	92
26	Amiodarone, Anticoagulation, andÂClinicalÂEvents in Patients WithÂAtrialÂFibrillation. Journal of the American College of Cardiology, 2014, 64, 1541-1550.	2.8	84
27	Longâ€ŧerm safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	7.1	69
28	Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality. European Journal of Heart Failure, 2018, 20, 572-581.	7.1	68
29	Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. ESC Heart Failure, 2018, 5, 120-128.	3.1	63
30	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. International Journal of Cardiology, 2016, 218, 150-157.	1.7	60
31	Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Annals of Intensive Care, 2017, 7, 6.	4.6	58
32	Comprehensive inâ€hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2018, 20, 1081-1099.	7.1	57
33	Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. European Journal of Heart Failure, 2020, 22, 290-299.	7.1	55
34	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50
35	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
36	Epidemiology of patients presenting with dyspnea to emergency departments in Europe and the Asia-Pacific region. European Journal of Emergency Medicine, 2019, 26, 345-349.	1.1	48

3

#	Article	IF	Citations
37	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	7.1	47
38	Morphine Use in the ED and Outcomes of Patients With Acute Heart Failure. Chest, 2017, 152, 821-832.	0.8	45
39	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
40	Current Use and Impact on 30-Day Mortality of Pulmonary Artery Catheter in Cardiogenic Shock Patients: Results From the CardShock Study. Journal of Intensive Care Medicine, 2020, 35, 1426-1433.	2.8	39
41	The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock – Results from the CardShock Study. International Journal of Cardiology, 2017, 226, 48-52.	1.7	38
42	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	3.2	37
43	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	3.0	37
44	Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. International Journal of Cardiology, 2017, 230, 191-197.	1.7	33
45	Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. PLoS ONE, 2019, 14, e0217006.	2.5	31
46	Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest. Journal of the American College of Cardiology, 2017, 70, 2652-2660.	2.8	30
47	Protein-based cardiogenic shock patient classifier. European Heart Journal, 2019, 40, 2684-2694.	2.2	30
48	Acute Heart Failure With and Without Concomitant Acute Coronary Syndromes: Patient Characteristics, Management, and Survival. Journal of Cardiac Failure, 2014, 20, 723-730.	1.7	29
49	Assessment of early treatment response by rapid cardiothoracic ultrasound in acute heart failure: Cardiac filling pressures, pulmonary congestion and mortality. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 311-320.	1.0	29
50	Editor's Choice-The role of the emergency department in the management of acute heart failure: An international perspective on education and research. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 421-429.	1.0	28
51	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clinical Research in Cardiology, 2018, 107, 214-221.	3.3	28
52	Use of levosimendan in acute heart failure. European Heart Journal Supplements, 2018, 20, 12-110.	0.1	27
53	Altered mental status predicts mortality in cardiogenic shock – results from the CardShock study. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 38-44.	1.0	26
54	A Clinical Study of Beta-Haemolytic Groups A, B, C and G Streptococcal Bacteremia in Adults over an 8-Year Period. Scandinavian Journal of Infectious Diseases, 1997, 29, 233-238.	1.5	25

#	Article	IF	CITATIONS
55	External validation and comparison of the CardShock and IABP-SHOCK II risk scores in real-world cardiogenic shock patients. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 16-24.	1.0	24
56	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. Journal of the American Heart Association, 2017, 6, .	3.7	20
57	IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards. Clinical Research in Cardiology, 2017, 106, 369-378.	3.3	17
58	Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. American Journal of Cardiology, 2017, 120, 1090-1097.	1.6	17
59	Survival and quality of life after early discharge in low-risk pulmonary embolism. European Respiratory Journal, 2021, 57, 2002368.	6.7	17
60	Performance of Early Capillary Refill Time Measurement on Outcomes in Cardiogenic Shock: An Observational, Prospective Multicentric Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1230-1238.	5.6	17
61	Comparison of the use of comprehensive point-of-care test panel to conventional laboratory process in emergency department. BMC Emergency Medicine, 2018, 18, 43.	1.9	15
62	Circulating levels of <scp>microRNA</scp> 423â€5p are associated with 90Âday mortality in cardiogenic shock. ESC Heart Failure, 2019, 6, 98-102.	3.1	15
63	Venous lactate improves the prediction of in-hospital adverse outcomes in normotensive pulmonary embolism. European Journal of Internal Medicine, 2021, 86, 25-31.	2.2	15
64	Short-term outcomes of heart failure patients with reduced and preserved ejection fraction after acute decompensation according to the final destination after emergency department care. Clinical Research in Cardiology, 2018, 107, 698-710.	<b>3.</b> 3	14
65	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	2.4	14
66	CTâ€IGFBPâ€4 as a novel prognostic biomarker in acute heart failure. ESC Heart Failure, 2020, 7, 434-444.	3.1	14
67	National Early Warning Score 2 (NEWS2) and 3-level triage scale as risk predictors in frail older adults in the emergency department. BMC Emergency Medicine, 2020, 20, 83.	1.9	13
68	Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock – Insights from the CardShock study. International Journal of Cardiology, 2021, 322, 191-196.	1.7	13
69	Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study. ESC Heart Failure, 2021, 8, 1398-1407.	3.1	13
70	Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock. Annals of Intensive Care, 2021, 11, 25.	4.6	13
71	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. Cardiac Failure Review, 2019, 5, 155-161.	3.0	13
72	Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. International Journal of Cardiology, 2016, 215, 26-31.	1.7	12

#	Article	IF	CITATIONS
73	Comparative Analysis of Short-Term Outcomes of Patients With Heart Failure With a Mid-Range Ejection Fraction After Acute Decompensation. American Journal of Cardiology, 2019, 123, 84-92.	1.6	12
74	Prognostic impact of baseline and residual SYNTAX scores in cardiogenic shock. Catheterization and Cardiovascular Interventions, 2019, 93, 1-8.	1.7	11
75	Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock. International Journal of Molecular Sciences, 2020, 21, 7925.	4.1	11
76	Outcome of patients with different clinical presentations of high-risk pulmonary embolism. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 787-796.	1.0	11
77	The effect of moderate exercise training on skeletal muscle myosin heavy chain distribution in chronic heart failure. International Journal of Cardiology, 2006, 109, 335-338.	1.7	10
78	Get with the guidelines: management of chronic obstructive pulmonary disease in emergency departments in Europe and Australasia is subâ€optimal. Internal Medicine Journal, 2020, 50, 200-208.	0.8	10
79	N-terminal Pro-brain Natriuretic Peptide, High-sensitivity Troponin and Pulmonary Artery Clot Score as Predictors of Right Ventricular Dysfunction in Echocardiography. Heart Lung and Circulation, 2016, 25, 592-599.	0.4	9
80	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 75-81.	3.0	9
81	The impact of emergency medical services in acute heart failure. International Journal of Cardiology, 2017, 232, 222-226.	1.7	8
82	Systematic geriatric assessment for older patients with frailty in the emergency department: a randomised controlled trial. BMC Geriatrics, 2021, 21, 408.	2.7	8
83	Preâ€hospital management protocols and perceived difficulty in diagnosing acute heart failure. ESC Heart Failure, 2020, 7, 290-297.	3.1	7
84	The role of preâ€hospital management in acute heart failure. European Journal of Heart Failure, 2017, 19, 287-289.	7.1	6
85	Predictive value of the baseline electrocardiogram STâ€segment pattern in cardiogenic shock: Results from the CardShock Study. Annals of Noninvasive Electrocardiology, 2018, 23, e12561.	1.1	6
86	Levels of Growth Differentiation Factor 15 and Early Mortality Risk Stratification in Cardiogenic Shock. Journal of Cardiac Failure, 2019, 25, 894-901.	1.7	6
87	Triage quality control is missing tools—a new observation technique for ED quality improvement. International Journal for Quality in Health Care, 2017, 29, 295-300.	1.8	5
88	Prevalence, Temporal Evolution, and Impact on Survival of Ventricular Conduction Blocks in Patients With Acute Coronary Syndrome and Cardiogenic Shock. American Journal of Cardiology, 2018, 122, 199-205.	1.6	5
89	Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study. Clinical Research in Cardiology, 2021, , 1.	3.3	5
90	The BRONCHâ€AHF study: effects on shortâ€term outcome of nebulized bronchodilators in emergency department patients diagnosed with acute heart failure. European Journal of Heart Failure, 2018, 20, 822-826.	7.1	4

#	Article	IF	CITATIONS
91	Treatment and outcome of adult patients with acute asthma in emergency departments in Australasia, South East Asia and Europe: Are guidelines followed? AANZDEM/EuroDEM study. EMA - Emergency Medicine Australasia, 2019, 31, 756-762.	1.1	4
92	Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis. Blood Coagulation and Fibrinolysis, 2019, 30, 188-192.	1.0	4
93	Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock. ESC Heart Failure, 2020, 7, 768-773.	3.1	4
94	Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrest—A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial. , 2021, 3, e0502.		4
95	Circulating MiRNA Dynamics in ST-Segment Elevation Myocardial Infarction-driven Cardiogenic Shock. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 783-786.	0.6	3
96	Seasonal variations of patients presenting dyspnea to emergency departments in Europe: Results from the EURODEM Study. Turkish Journal of Medical Sciences, 2020, 50, 1879-1886.	0.9	3
97	Low body temperature and mortality in older patients with frailty in the emergency department. Aging Clinical and Experimental Research, 2022, 34, 1453-1457.	2.9	3
98	Epidemiology, treatment and outcome of patients with lower respiratory tract infection presenting to emergency departments with dyspnoea ( AANZDEM and EuroDEM studies). EMA - Emergency Medicine Australasia, 2021, 33, 58-66.	1.1	0
99	Reply to: High levels of plasma biomarkers at 24Âh were found to be strong predictors of 90-day mortality: beware of some potential confounders!. Annals of Intensive Care, 2021, 11, 46.	4.6	O
100	The emergency department arrival mode and its relations to ED management and 30-day mortality in acute heart failure: an ancillary analysis from the EURODEM study. BMC Emergency Medicine, 2022, 22, 27.	1.9	0